EPO and anemia (phenotype): Our group compared the effects of FCM and ferric gluconate on anemia in HD patients, highlighting a reduction in the erythropoietin (ESA) dose in 4 years of follow-up during FCM treatment, via the better control of anemia mediated by high levels of ferritin and TSAT, and a reduction in the erythropoietin resistance index [11].